-
ASH China Voice丨Zunmin Zhu / Mingfeng Zhao / Wenyi Lu: IL-18 and RQR8 Suicide-Switch Dual-Armored CLL-1 CAR-T Cells Enhance the Efficacy and Safety of AML Therapy
The 67th American Society of Hematology (ASH) Annual Meeting will be held from December 6 to 9, 2025, in Orlando, USA. As one of the largest, most influential, and most comprehensive international congresses in hematology, ASH attracts tens of thousands of experts and scholars from around the world each year to share the latest advances…
-
Professor Ye Xiongjun: From Systemic Therapy to Minimally Invasive Surgery — What “Surprises” Await in Kidney Cancer Treatment?
In recent years, the incidence of urological malignancies in China has risen steadily. Prostate, bladder, and kidney cancers now rank among the most common malignancies in the country, posing a serious threat to public health. The Department of Urology at the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS), has long…
-
Precision Targeted Therapy for Bladder Cancer Reaches a New Milestone: Professor Xu Tao’s Team from Peking University People’s Hospital Demonstrates Potent Synergistic Effects Through Combination Treatment
Bladder cancer is one of the most common malignant tumors of the genitourinary system. In recent years, the emergence of antibody-drug conjugates (ADCs) has brought new hope for patients with advanced bladder cancer. Among them, Enfortumab Vedotin (EV) — an ADC targeting the tumor antigen Nectin-4 — has been hailed as a “precision-guided missile.” However,…
-
NCCU 2025 | When Urologic Surgery Meets the Wave of Innovation: Technology, Clinical Practice, and Young Talent Development Drive the Field Forward
Editor’s Note: In recent years, the incidence of urologic cancers in China has continued to rise, with prostate, bladder, and kidney cancers now among the most common malignancies nationwide—posing a…
-
Adv Sci | MARCO⁺ Tumor-Associated Macrophages Drive Immunotherapy Resistance in Renal Cell Carcinoma
Renal cell carcinoma (RCC) is the most common subtype of kidney cancer and continues to rise in incidence worldwide. RCC is also regarded as one of the most immune- and…
-
NCCU 2025 | Prof. Sujun Han: Enhancing Outcomes in Urologic Oncology Through Quality Control and Emerging Therapeutic Strategies
Editor’s Note: In recent years, the incidence of urologic malignancies in China has continued to rise, with prostate, bladder, and kidney cancers now ranking among the most common tumors nationwide…
-
NCCU 2025 | Prof. Peter Hammerer Discusses Precision Surgery and Radiotherapy Decision-Making in Oligometastatic Prostate Cancer
Editor’s Note: Oligometastatic prostate cancer occupies a unique clinical space—it is neither confined entirely to the prostate nor widely metastatic throughout the body. This intermediate state presents distinct therapeutic challenges…
-
NCCU 2025 | Professor Yong Zhang Explains the Advantages, Beneficiaries, and Learning Path of the “Xing’s Neobladder” Technique
Bladder cancer is one of the most common malignancies of the urinary system. Radical cystectomy remains one of the standard treatments, and urinary diversion is a crucial component of this complex procedure.Professor Xing Nianzeng and his team pioneered a novel laparoscopic-friendly orthotopic ileal neobladder reconstruction technique, known as the “Xing’s Neobladder.” This innovative approach utilizes…
Connecting Medical Expertise through Media